Higher detection; mortality was not tested.
Understand it / 20 seconds
How can AI help medicine?
AI can help interpret images, identify patterns, organize clinical information, and accelerate parts of scientific discovery. A useful model output is not the same as a safe treatment: laboratory work, clinical trials, regulation, and clinician judgment still matter.
02Show meFollow the connection
- 01Medical or biological data
- 02Model
- 03Candidate or signal
- 04Validation
- 05Clinical use
Here's what matters
The answer changes when these conditions change.
- 01Was the result validated outside the training data?
- 02Is the intended use specific and regulated?
- 03Who is represented in the data?
- 04Does performance hold in real clinical settings?
- 05Does a clinician remain accountable?
Medicine / Choose the endpoint
“AI accuracy” is not a patient outcome.
Detection, workload, recalls, false positives, time to diagnosis, treatment, and mortality answer different questions.
Screen→Read→Recall→Diagnose→Treat→Outcome
03Prove itOpen the machinery
Inspect the claims behind this answer.
Each layer shows evidence type, geography, assumptions, caveats, review date, and original sources.
Observed
In the blind CASP14 assessment, AlphaFold predicted protein structures with accuracy competitive with experimental structures in a majority of evaluated cases.
This made an important scientific bottleneck more tractable; it did not replace laboratory validation or cure a disease.
Observed
The FDA maintains a growing list of AI-enabled medical devices authorized for U.S. marketing after applicable premarket review.
This is real clinical infrastructure, but authorization is device- and intended-use-specific.
Peer-reviewed study
In AITIC, cancer detection increased from about 6.3 to 7.3 per 1,000 screenings while radiologist reading workload fell about 63.6%.
In AITIC, cancer detection increased from about 6.3 to 7.3 per 1,000 screenings while radiologist reading workload fell about 63.6%.
Peer-reviewed study
In AITIC, recall rates increased from about 4.8% to 5.5%—a tradeoff alongside higher cancer detection.
In AITIC, recall rates increased from about 4.8% to 5.5%—a tradeoff alongside higher cancer detection.
Randomized trial
In LungIMPACT, median time to CT was about 53 days in both arms and time to lung-cancer diagnosis was about 44 versus 46 days, with no statistically meaningful acceleration of the targeted pathway.
In LungIMPACT, median time to CT was about 53 days in both arms and time to lung-cancer diagnosis was about 44 versus 46 days, with no statistically meaningful acceleration of the targeted pathway.